Spots Global Cancer Trial Database for abiraterone acetate
Every month we try and update this database with for abiraterone acetate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Abiraterone Post Ketoconazole for Prostate Cancer | NCT01199146 | Prostate Cancer | Abiraterone ace... | 18 Years - | University of California, San Francisco | |
| Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | NCT06136624 | Prostate Cancer... | Opevesostat Abiraterone ace... Enzalutamide Hydrocortisone Fludrocortisone... Prednisone Dexamethasone | - | Merck Sharp & Dohme LLC | |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | NCT02960022 | Prostate Cancer | enzalutamide abiraterone ace... prednisone | 18 Years - | Astellas Pharma Inc | |
| Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer | NCT02025010 | Castration-resi... | abiraterone ace... | 18 Years - | Dana-Farber Cancer Institute | |
| Abiraterone Acetate in Combination With Tildrakizumab | NCT04458311 | Metastatic Cast... | Abiraterone Ace... Tildrakizumab | 18 Years - | Institute of Cancer Research, United Kingdom | |
| Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. | NCT05422911 | Metastatic Canc... Neoplasm, Prost... | Abiraterone ace... Apalutamide Enzalutamide | - | James J. Peters Veterans Affairs Medical Center | |
| Tissue Predictors of Abiraterone Benefit | NCT03176381 | Metastatic Cast... | 18 Years - | Tianjin Medical University Second Hospital | ||
| Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability | NCT02663193 | Prostate Cancer | No Intervention | 18 Years - | Janssen Scientific Affairs, LLC | |
| An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT02257736 | Prostatic Neopl... | Apalutamide Abiraterone ace... Prednisone Placebo | 18 Years - | Aragon Pharmaceuticals, Inc. | |
| A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder | NCT05137262 | Urothelial Carc... Bladder Cancer | Abiraterone ace... Durvalumab Methotrexate Vinblastine Doxorubicin Hyd... Cisplatin | 18 Years - | M.D. Anderson Cancer Center | |
| Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT05520138 | Prostatic Neopl... | Enzalutamide Abiraterone ace... | 18 Years - | Pfizer | |
| A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer | NCT01685983 | Prostate Cancer | Abiraterone ace... Prednisolone | 18 Years - | Janssen Research & Development, LLC | |
| Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer | NCT03360721 | Castration-Resi... Prostate Adenoc... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Abiraterone Ace... Apalutamide Prednisone | 18 Years - | M.D. Anderson Cancer Center | |
| A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT00910754 | Prostate Neopla... | Abiraterone ace... Prednisone | 18 Years - | Janssen Research & Development, LLC | |
| A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01424930 | Prostate Neopla... Prostate Cancer | Abiraterone Prednisone | 18 Years - | Janssen-Ortho Inc., Canada | |
| Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01576172 | Castration-Resi... Recurrent Prost... Stage IV Prosta... | Abiraterone Ace... Laboratory Biom... Prednisone Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) | NCT02034552 | Prostatic Neopl... | Radium-223 dich... Abiraterone ace... Prednisone Enzalutamide | 18 Years - | Bayer | |
| Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer | NCT04262154 | Metastatic Pros... | Atezolizumab Abiraterone Prednisone GnRH analog Stereotactic Bo... Enzalutamide Follow up | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer | NCT03821792 | Metastatic Pros... Prostate Adenoc... Prostate Carcin... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Abiraterone Ace... Apalutamide Prednisone | 18 Years - | M.D. Anderson Cancer Center | |
| Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate | NCT03356444 | Prostate Cancer Castration-resi... Drug | Abiraterone Ace... Docetaxel | 40 Years - | West China Hospital | |
| Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate | NCT01792687 | Prostate Cancer | ARN-509 Abiraterone ace... Prednisone | 18 Years - | Aragon Pharmaceuticals, Inc. | |
| Abiraterone Acetate in Combination With Tildrakizumab | NCT04458311 | Metastatic Cast... | Abiraterone Ace... Tildrakizumab | 18 Years - | Institute of Cancer Research, United Kingdom | |
| Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer | NCT03649841 | Castration-Sens... Metastatic Mali... Metastatic Pros... Prostate Adenoc... Prostate Small ... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Antiandrogen Th... Abiraterone Ace... Prednisone Radiation Thera... | 18 Years - | University of Washington | |
| A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01017939 | Prostate Neopla... | Abiraterone ace... Prednisone Dextromethorpha... Theophylline | 18 Years - | Janssen Research & Development, LLC | |
| Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | NCT00887198 | Prostate Cancer | Abiraterone ace... Placebo Prednisone | 18 Years - | Janssen Research & Development, LLC | |
| PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate. | NCT02787837 | Advanced Prosta... Abiraterone ACe... | 18 Years - 99 Years | Centro Nacional de Investigaciones Oncologicas CARLOS III | ||
| An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma | NCT00544440 | Prostate Neopla... | Abiraterone ace... Prednisone | 18 Years - | Janssen Research & Development, LLC | |
| Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) | NCT02987543 | Metastatic Cast... | olaparib enzalutamide abiraterone ace... abiraterone ace... enzalutamide | 18 Years - 130 Years | AstraZeneca | |
| Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01576172 | Castration-Resi... Recurrent Prost... Stage IV Prosta... | Abiraterone Ace... Laboratory Biom... Prednisone Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Phase 1 Study of ATRS-2002 in Healthy Male Adults | NCT04879589 | Metastatic Cast... | Abiraterone Ace... | 18 Years - 55 Years | Syneos Health | |
| A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01834209 | Prostate Neopla... | Abiraterone ace... Prednisone or p... | 18 Years - | Janssen Research & Development, LLC | |
| Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer | NCT01023061 | Adenocarcinoma ... Stage II Prosta... Stage III Prost... Stage IV Prosta... | abiraterone ace... prednisone leuprolide acet... laboratory biom... external beam r... goserelin aceta... | 18 Years - | University of Washington | |
| Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer | NCT01393730 | Prostate Cancer | Abiraterone ace... Dutasteride Prednisone | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer | NCT05376722 | Neoadjuvant The... | pamiparib abiraterone prednisone | 18 Years - 80 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) | NCT03834519 | Prostatic Neopl... | Pembrolizumab Olaparib Abiraterone ace... Prednisone Enzalutamide Prednisolone | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | NCT02960022 | Prostate Cancer | enzalutamide abiraterone ace... prednisone | 18 Years - | Astellas Pharma Inc | |
| Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer | NCT03565835 | Prostatic Neopl... | Abiraterone Ace... Prednisone | 18 Years - | Montefiore Medical Center | |
| Tissue Predictors of Abiraterone Benefit | NCT03176381 | Metastatic Cast... | 18 Years - | Tianjin Medical University Second Hospital | ||
| Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | NCT01503229 | Hormone-Resista... Metastatic Pros... Recurrent Prost... Stage IV Prosta... | Abiraterone Ace... Laboratory Biom... Pharmacological... Prednisone | 18 Years - | University of Washington | |
| Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | NCT06430411 | Prostate Cancer... Prostate Cancer... Prostate Cancer Prostate Neopla... Oligometastatic... Oligometastasis | Radical prostat... Prostate irradi... Surgical metast... Irradiation of ... Abiraterone ace... Enzalutamide Darolutamide Apalutamide Docetaxel Lutetium-PSMA Androgen depriv... | 18 Years - 80 Years | Medical University of Vienna | |
| Abiraterone Acetate in Molecular Apocrine Breast Cancer | NCT01842321 | Breast Cancer | Abiraterone Ace... | 18 Years - | UNICANCER | |
| A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer | NCT02123758 | Prostatic Neopl... Metastatic Cast... | Abiraterone Ace... Prednisone JNJ-56021927 | 18 Years - 99 Years | Aragon Pharmaceuticals, Inc. | |
| Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients | NCT06193993 | Prostate Cancer Metastatic Canc... Hormone Sensiti... Castration-resi... | Abiraterone Ace... | 21 Years - 99 Years | National University Hospital, Singapore | |
| Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer | NCT03098836 | Prostate Cancer | ARN-509 Abiraterone Ace... Prednisone | 18 Years - | Duke University | |
| A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer | NCT01957436 | Metastatic Pros... | abiraterone ace... radiotherapy Androgen Depriv... Docetaxel | 18 Years - | UNICANCER | |
| A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer | NCT03706365 | Prostate Cancer | Abemaciclib Abiraterone Ace... Prednisone Placebo | 18 Years - | Eli Lilly and Company | |
| Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study | NCT04175431 | Prostate Adenoc... | Positron Emissi... Lymphadenectomy Radiation Thera... Abiraterone Ace... Prednisone Computed Tomogr... Abiraterone PSMA PET Scan | 18 Years - | University of Washington | |
| Phase 1 Study of ATRS-2002 in Healthy Male Adults | NCT04879589 | Metastatic Cast... | Abiraterone Ace... | 18 Years - 55 Years | Syneos Health | |
| Abiraterone Post Ketoconazole for Prostate Cancer | NCT01199146 | Prostate Cancer | Abiraterone ace... | 18 Years - | University of California, San Francisco | |
| Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer | NCT01786265 | Prostate Adenoc... Recurrent Prost... | Abiraterone Ace... Bicalutamide Degarelix Flutamide Goserelin Aceta... Leuprolide Acet... Nilutamide Prednisone | 18 Years - | M.D. Anderson Cancer Center | |
| Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate | NCT04736108 | Prostate Cancer | Abiraterone ace... Prednisolone Goserelin | 18 Years - | West China Hospital | |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | NCT02960022 | Prostate Cancer | enzalutamide abiraterone ace... prednisone | 18 Years - | Astellas Pharma Inc | |
| Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | NCT01685125 | Hormone-resista... Recurrent Prost... Stage IV Prosta... | abiraterone ace... dasatinib prednisone | 18 Years - | University of Southern California | |
| A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01017939 | Prostate Neopla... | Abiraterone ace... Prednisone Dextromethorpha... Theophylline | 18 Years - | Janssen Research & Development, LLC | |
| Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer | NCT05212857 | Prostate Cancer | Leuprolide acet... Goserelin aceta... Triptorelin ace... Degarelix aceta... Abiraterone ace... Apalutamide Enzalutamide Local treatment... Radiotherapy fo... Radiotherapy fo... | 18 Years - 80 Years | Fudan University | |
| Assessment of New Molecular Imaging Strategies for Prostate Cancer | NCT02813226 | Prostate Cancer | Molecular Imagi... | 18 Years - | Ontario Clinical Oncology Group (OCOG) | |
| A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer | NCT02123758 | Prostatic Neopl... Metastatic Cast... | Abiraterone Ace... Prednisone JNJ-56021927 | 18 Years - 99 Years | Aragon Pharmaceuticals, Inc. | |
| S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy | NCT01309672 | Prostate Cancer | abiraterone ace... Prednisone | 18 Years - 120 Years | SWOG Cancer Research Network | |
| PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NCT04556617 | Metastatic Cast... | PLX2853 Olaparib Abiraterone ace... Prednisone | 18 Years - | Opna Bio LLC | |
| A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer | NCT06320067 | Prostate Cancer... | Stereotactic Ab... 177Lu-PSMA-617 Niraparib and A... Abiraterone Ace... Apalutamide Androgen Depriv... Androgen Recept... Local Radiother... Prednisolone Docetaxel | 18 Years - | University College, London | |
| Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer | NCT04356430 | Prostate Cancer | Abiraterone Ace... Prednisone Goserelin 10.8 ... | 18 Years - 75 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| cARdiotoxicity Profile of aBIraTeRone in prostAte Cancer : a pharmacoviGilancE Study | NCT03243604 | Arrhythmias, Ca... Atrial Fibrilla... Tachycardia, Su... Cardiac Failure | L02 (sex hormon... | 18 Years - | Groupe Hospitalier Pitie-Salpetriere | |
| A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer | NCT03748641 | Castration-Resi... | Niraparib Abiraterone Ace... Prednisone Placebo New Formulation... | 18 Years - | Janssen Research & Development, LLC | |
| Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent | NCT02485691 | Prostate Cancer... | cabazitaxel XRP... enzalutamide abiraterone ace... prednisone | 18 Years - | Sanofi | |
| Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | NCT02268175 | Prostate Adenoc... Prostate Cancer High Risk Prost... | Enzalutamide Abiraterone Ace... Prednisone Leuprolide Acet... | 18 Years - | Dana-Farber Cancer Institute | |
| Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer | NCT01511536 | Prostate Cancer | Cabazitaxel XRP... Abiraterone ace... Prednisone 5 mg | 18 Years - | Sanofi | |
| A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy | NCT02405858 | Metastatic Cast... | Abiraterone Ace... Prednisolone | 20 Years - | Janssen Pharmaceutical K.K. | |
| Abiraterone-Rechallenge Study for CRPC Patients | NCT02656615 | Prostate Cancer | abiraterone ace... | 18 Years - 100 Years | Cantonal Hospital of St. Gallen | |
| A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT05295927 | Prostatic Neopl... | EPI-7386 Abiraterone Ace... Prednisone or P... Apalutamide | 18 Years - | Janssen Research & Development, LLC | |
| Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer | NCT01543776 | Castration-resi... Stage IV Prosta... | abiraterone ace... | - | University of Chicago | |
| Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer | NCT04947254 | Prostate Carcin... Stage IIC Prost... Stage III Prost... Stage IIIA Pros... Stage IIIB Pros... Stage IIIC Pros... Stage IVA Prost... | Abiraterone Ace... Antiandrogen Th... Apalutamide Biopsy Niraparib Prednisone Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | NCT02268175 | Prostate Adenoc... Prostate Cancer High Risk Prost... | Enzalutamide Abiraterone Ace... Prednisone Leuprolide Acet... | 18 Years - | Dana-Farber Cancer Institute | |
| Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects | NCT03012321 | Prostate Cancer... Abnormal DNA Re... Metastatic Pros... Stage IV Prosta... | Olaparib Abiraterone Ace... Prednisone | 18 Years - | Northwestern University | |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer | NCT04071262 | Advanced Cancer | Abemaciclib Abiraterone Ace... Prednisolone | 20 Years - | Eli Lilly and Company | |
| Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | NCT06430411 | Prostate Cancer... Prostate Cancer... Prostate Cancer Prostate Neopla... Oligometastatic... Oligometastasis | Radical prostat... Prostate irradi... Surgical metast... Irradiation of ... Abiraterone ace... Enzalutamide Darolutamide Apalutamide Docetaxel Lutetium-PSMA Androgen depriv... | 18 Years - 80 Years | Medical University of Vienna | |
| Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer | NCT04056754 | Metastatic Cast... | Abiraterone Ace... Placebo Prednisone | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer | NCT03649841 | Castration-Sens... Metastatic Mali... Metastatic Pros... Prostate Adenoc... Prostate Small ... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Antiandrogen Th... Abiraterone Ace... Prednisone Radiation Thera... | 18 Years - | University of Washington | |
| Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer | NCT03098836 | Prostate Cancer | ARN-509 Abiraterone Ace... Prednisone | 18 Years - | Duke University | |
| A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy | NCT03043807 | Prostate Cancer | Leuprolide Acet... Docetaxel Bicalutamide Radiation Abiraterone Ace... | 18 Years - 80 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer | NCT04071262 | Advanced Cancer | Abemaciclib Abiraterone Ace... Prednisolone | 20 Years - | Eli Lilly and Company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
